Format

Send to

Choose Destination
Cell Death Differ. 2011 Oct;18(10):1608-16. doi: 10.1038/cdd.2011.23. Epub 2011 Apr 1.

Abl interconnects oncogenic Met and p53 core pathways in cancer cells.

Author information

1
Developmental Biology Institute of Marseille-Luminy (IBDML), UMR 6216, CNRS - Inserm - Université de la Méditerranée, Campus de Luminy-Case 907, 13288 Marseille Cedex 9, France.

Abstract

The simplicity of BCR-ABL 'oncogene addiction' characterizing leukemia contrasts with the complexity of solid tumors where multiple 'core pathways', including receptor tyrosine kinases (RTKs) and p53, are often altered. This discrepancy illustrates the limited success of RTK antagonists in solid tumor treatment compared with the impact of Imatinib in BCR-ABL-dependent leukemia. Here, we identified c-Abl as a signaling node interconnecting Met-RTK and p53 core pathways, and showed that its inhibition impairs Met-dependent tumorigenesis. Met ensures cell survival through a new path in which c-Abl and p38-MAPK are employed to elicit p53 phosphorylation on Ser(392) and Mdm2 upregulation. We found a clinical correlation between activated Met, phospho-p53, and Mdm2 levels in human tumors, supporting the role of this path in tumorigenesis. Our findings introduce the concept that RTK-driven tumors may be therapeutically treated by hitting signaling nodes interconnecting core pathways. Moreover, they underline the importance of evaluating the relevance of c-Abl antagonists for combined therapies, based on the tumor signaling signature.

PMID:
21455220
PMCID:
PMC3172114
DOI:
10.1038/cdd.2011.23
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center